Diabetes and the association of postoperative hyperglycemia with clinical and economic outcomes in cardiac surgery

Giampaolo Greco, Bart S. Ferket, David A. D'Alessandro, Wei Shi, Keith A. Horvath, Alexander Rosen, Stacey Welsh, Emilia Bagiella, Alexis E. Neill, Deborah L. Williams, Ann Greenberg, Jeffrey N. Browndyke, A. Marc Gillinov, Mary Lou Mayer, Jessica Keim-Malpass, Lopa S. Gupta, Samuel F. Hohmann, Annetine C. Gelijns, Patrick T. O'Gara, Alan J. Moskowitz

Research output: Contribution to journalArticle

Abstract

Objective The management of postoperative hyperglycemia is controversial and generally does not take into account pre-existing diabetes. We analyzed clinical and economic outcomes associated with postoperative hyperglycemia in cardiac surgery patients, stratifying by diabetes status. Research Design and Methods Multicenter cohort study in 4,316 cardiac surgery patients operated on in 2010. Glucose was measured at 6-h intervals for 48 h postoperatively. Outcomes included cost, hospital length of stay (LOS), cardiac and respiratory complications, major infections, and death. Associations between maximum glucose levels and outcomes were assessed with multivariable regression and recycled prediction analyses. Results In patients without diabetes, increasing glucose levels were associated with a gradual worsening of outcomes. In these patients, hyperglycemia (≥180 mg/dL) was associated with an additional cost of $3,192 (95% CI 1,972 to 4,456), an additional hospital LOS of 0.8 days (0.4 to 1.3), an increase in infections of 1.6% (0.5 to 2.8), and an increase in respiratory complications of 2.6% (0.0 to 5.3). However, among patients with insulin-treated diabetes, optimal outcomes were associated with glucose levels considered to be hyperglycemic (180 to 240 mg/dL). This level of hyperglycemia was associated with cost reductions of $6,225 (212,886 to 2222), hospital LOS reductions of 1.6 days (23.7 to 0.4), infection reductions of 4.1% (29.1 to 0.0), and reductions in respiratory complication of 12.5% (222.4 to 23.0). In patients with non-insulin-treated diabetes, outcomes did not differ significantly when hyperglycemia was present. Conclusions Glucose levels

Original languageEnglish (US)
Pages (from-to)408-417
Number of pages10
JournalDiabetes Care
Volume39
Issue number3
DOIs
StatePublished - Mar 1 2016
Externally publishedYes

Fingerprint

Hyperglycemia
Thoracic Surgery
Length of Stay
Economics
Glucose
Costs and Cost Analysis
Infection
Multicenter Studies
Cohort Studies
Research Design
Insulin

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Advanced and Specialized Nursing

Cite this

Greco, G., Ferket, B. S., D'Alessandro, D. A., Shi, W., Horvath, K. A., Rosen, A., ... Moskowitz, A. J. (2016). Diabetes and the association of postoperative hyperglycemia with clinical and economic outcomes in cardiac surgery. Diabetes Care, 39(3), 408-417. https://doi.org/10.2337/dc15-1817

Diabetes and the association of postoperative hyperglycemia with clinical and economic outcomes in cardiac surgery. / Greco, Giampaolo; Ferket, Bart S.; D'Alessandro, David A.; Shi, Wei; Horvath, Keith A.; Rosen, Alexander; Welsh, Stacey; Bagiella, Emilia; Neill, Alexis E.; Williams, Deborah L.; Greenberg, Ann; Browndyke, Jeffrey N.; Gillinov, A. Marc; Mayer, Mary Lou; Keim-Malpass, Jessica; Gupta, Lopa S.; Hohmann, Samuel F.; Gelijns, Annetine C.; O'Gara, Patrick T.; Moskowitz, Alan J.

In: Diabetes Care, Vol. 39, No. 3, 01.03.2016, p. 408-417.

Research output: Contribution to journalArticle

Greco, G, Ferket, BS, D'Alessandro, DA, Shi, W, Horvath, KA, Rosen, A, Welsh, S, Bagiella, E, Neill, AE, Williams, DL, Greenberg, A, Browndyke, JN, Gillinov, AM, Mayer, ML, Keim-Malpass, J, Gupta, LS, Hohmann, SF, Gelijns, AC, O'Gara, PT & Moskowitz, AJ 2016, 'Diabetes and the association of postoperative hyperglycemia with clinical and economic outcomes in cardiac surgery', Diabetes Care, vol. 39, no. 3, pp. 408-417. https://doi.org/10.2337/dc15-1817
Greco, Giampaolo ; Ferket, Bart S. ; D'Alessandro, David A. ; Shi, Wei ; Horvath, Keith A. ; Rosen, Alexander ; Welsh, Stacey ; Bagiella, Emilia ; Neill, Alexis E. ; Williams, Deborah L. ; Greenberg, Ann ; Browndyke, Jeffrey N. ; Gillinov, A. Marc ; Mayer, Mary Lou ; Keim-Malpass, Jessica ; Gupta, Lopa S. ; Hohmann, Samuel F. ; Gelijns, Annetine C. ; O'Gara, Patrick T. ; Moskowitz, Alan J. / Diabetes and the association of postoperative hyperglycemia with clinical and economic outcomes in cardiac surgery. In: Diabetes Care. 2016 ; Vol. 39, No. 3. pp. 408-417.
@article{22917c7481d24649815ddbe6ef45b7cd,
title = "Diabetes and the association of postoperative hyperglycemia with clinical and economic outcomes in cardiac surgery",
abstract = "Objective The management of postoperative hyperglycemia is controversial and generally does not take into account pre-existing diabetes. We analyzed clinical and economic outcomes associated with postoperative hyperglycemia in cardiac surgery patients, stratifying by diabetes status. Research Design and Methods Multicenter cohort study in 4,316 cardiac surgery patients operated on in 2010. Glucose was measured at 6-h intervals for 48 h postoperatively. Outcomes included cost, hospital length of stay (LOS), cardiac and respiratory complications, major infections, and death. Associations between maximum glucose levels and outcomes were assessed with multivariable regression and recycled prediction analyses. Results In patients without diabetes, increasing glucose levels were associated with a gradual worsening of outcomes. In these patients, hyperglycemia (≥180 mg/dL) was associated with an additional cost of $3,192 (95{\%} CI 1,972 to 4,456), an additional hospital LOS of 0.8 days (0.4 to 1.3), an increase in infections of 1.6{\%} (0.5 to 2.8), and an increase in respiratory complications of 2.6{\%} (0.0 to 5.3). However, among patients with insulin-treated diabetes, optimal outcomes were associated with glucose levels considered to be hyperglycemic (180 to 240 mg/dL). This level of hyperglycemia was associated with cost reductions of $6,225 (212,886 to 2222), hospital LOS reductions of 1.6 days (23.7 to 0.4), infection reductions of 4.1{\%} (29.1 to 0.0), and reductions in respiratory complication of 12.5{\%} (222.4 to 23.0). In patients with non-insulin-treated diabetes, outcomes did not differ significantly when hyperglycemia was present. Conclusions Glucose levels",
author = "Giampaolo Greco and Ferket, {Bart S.} and D'Alessandro, {David A.} and Wei Shi and Horvath, {Keith A.} and Alexander Rosen and Stacey Welsh and Emilia Bagiella and Neill, {Alexis E.} and Williams, {Deborah L.} and Ann Greenberg and Browndyke, {Jeffrey N.} and Gillinov, {A. Marc} and Mayer, {Mary Lou} and Jessica Keim-Malpass and Gupta, {Lopa S.} and Hohmann, {Samuel F.} and Gelijns, {Annetine C.} and O'Gara, {Patrick T.} and Moskowitz, {Alan J.}",
year = "2016",
month = "3",
day = "1",
doi = "10.2337/dc15-1817",
language = "English (US)",
volume = "39",
pages = "408--417",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "3",

}

TY - JOUR

T1 - Diabetes and the association of postoperative hyperglycemia with clinical and economic outcomes in cardiac surgery

AU - Greco, Giampaolo

AU - Ferket, Bart S.

AU - D'Alessandro, David A.

AU - Shi, Wei

AU - Horvath, Keith A.

AU - Rosen, Alexander

AU - Welsh, Stacey

AU - Bagiella, Emilia

AU - Neill, Alexis E.

AU - Williams, Deborah L.

AU - Greenberg, Ann

AU - Browndyke, Jeffrey N.

AU - Gillinov, A. Marc

AU - Mayer, Mary Lou

AU - Keim-Malpass, Jessica

AU - Gupta, Lopa S.

AU - Hohmann, Samuel F.

AU - Gelijns, Annetine C.

AU - O'Gara, Patrick T.

AU - Moskowitz, Alan J.

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Objective The management of postoperative hyperglycemia is controversial and generally does not take into account pre-existing diabetes. We analyzed clinical and economic outcomes associated with postoperative hyperglycemia in cardiac surgery patients, stratifying by diabetes status. Research Design and Methods Multicenter cohort study in 4,316 cardiac surgery patients operated on in 2010. Glucose was measured at 6-h intervals for 48 h postoperatively. Outcomes included cost, hospital length of stay (LOS), cardiac and respiratory complications, major infections, and death. Associations between maximum glucose levels and outcomes were assessed with multivariable regression and recycled prediction analyses. Results In patients without diabetes, increasing glucose levels were associated with a gradual worsening of outcomes. In these patients, hyperglycemia (≥180 mg/dL) was associated with an additional cost of $3,192 (95% CI 1,972 to 4,456), an additional hospital LOS of 0.8 days (0.4 to 1.3), an increase in infections of 1.6% (0.5 to 2.8), and an increase in respiratory complications of 2.6% (0.0 to 5.3). However, among patients with insulin-treated diabetes, optimal outcomes were associated with glucose levels considered to be hyperglycemic (180 to 240 mg/dL). This level of hyperglycemia was associated with cost reductions of $6,225 (212,886 to 2222), hospital LOS reductions of 1.6 days (23.7 to 0.4), infection reductions of 4.1% (29.1 to 0.0), and reductions in respiratory complication of 12.5% (222.4 to 23.0). In patients with non-insulin-treated diabetes, outcomes did not differ significantly when hyperglycemia was present. Conclusions Glucose levels

AB - Objective The management of postoperative hyperglycemia is controversial and generally does not take into account pre-existing diabetes. We analyzed clinical and economic outcomes associated with postoperative hyperglycemia in cardiac surgery patients, stratifying by diabetes status. Research Design and Methods Multicenter cohort study in 4,316 cardiac surgery patients operated on in 2010. Glucose was measured at 6-h intervals for 48 h postoperatively. Outcomes included cost, hospital length of stay (LOS), cardiac and respiratory complications, major infections, and death. Associations between maximum glucose levels and outcomes were assessed with multivariable regression and recycled prediction analyses. Results In patients without diabetes, increasing glucose levels were associated with a gradual worsening of outcomes. In these patients, hyperglycemia (≥180 mg/dL) was associated with an additional cost of $3,192 (95% CI 1,972 to 4,456), an additional hospital LOS of 0.8 days (0.4 to 1.3), an increase in infections of 1.6% (0.5 to 2.8), and an increase in respiratory complications of 2.6% (0.0 to 5.3). However, among patients with insulin-treated diabetes, optimal outcomes were associated with glucose levels considered to be hyperglycemic (180 to 240 mg/dL). This level of hyperglycemia was associated with cost reductions of $6,225 (212,886 to 2222), hospital LOS reductions of 1.6 days (23.7 to 0.4), infection reductions of 4.1% (29.1 to 0.0), and reductions in respiratory complication of 12.5% (222.4 to 23.0). In patients with non-insulin-treated diabetes, outcomes did not differ significantly when hyperglycemia was present. Conclusions Glucose levels

UR - http://www.scopus.com/inward/record.url?scp=84962054162&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962054162&partnerID=8YFLogxK

U2 - 10.2337/dc15-1817

DO - 10.2337/dc15-1817

M3 - Article

VL - 39

SP - 408

EP - 417

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 3

ER -